The case for & against
Bull & Bear analysis
Bearish
SOPHiA GENETICS (NASDAQ: SOPH) is a pioneering player in the genomic data analytics and precision medicine sector. The company operates a unique AI-driven platform that facilitates comprehensive genomic analysis aimed at improving patient outcomes, particularly in oncology and rare diseases. SOPHiA stands out within its growing field by evolving healthcare diagnostics with a focus on decentralized testing solutions and strategic collaborations, such as recent partnerships with major biopharmaceutical firms including AstraZeneca.
Bull says
- ↑Q1 2026 revenue reached $21.7M, up 22% YoY with 108k analyses performed.
- ↑Net dollar retention of 117% indicates strong customer account expansion.
- ↑Core genomic customer count rose to 537 from 490 in Q1 2025.
- ↑Dividend yield of 1.23% and positive earnings revisions support shareholder returns.
- ↑Analysts maintain a Strong Buy rating and $8 price target (33% upside).
- ↑High-quality score reflects solid balance sheet resilience amid market pressure.
Bear says
- ↓Negative earnings yield and weak profitability metrics undermine return prospects.
- ↓Q1 cash burn increased to $19.5M, raising liquidity and funding concerns.
- ↓Patent infringement litigation cost $1.4M in Q1, adding regulatory uncertainty.
- ↓Execution risk in scaling could delay customer onboarding and revenue recognition.
- ↓Churn among smaller accounts (<$8k average revenue) signals engagement issues.
- ↓Negative liquidity factor and currency risks may pressure non-USD revenues.
Earnings Call · Q1 2025 · Mgmt. Guidance
Updated 06-02-2026neutral
Transcript signals
Bull points
- Total revenue for the first quarter of 2025 was $17.8 million, compared to $15.8 million for the first quarter of 2024, representing year-over-year growth of 13%.
- Gross profit for the quarter was $12.2 million compared to gross profit of $10.4 million in the prior year period, representing year-over-year growth of 17%.
- Adjusted gross profit was 13.4 million, an increase of 21% compared to adjusted gross profit of 11.1 million in the prior year period.
Bear points
- Operating loss for the quarter was 16 million compared to 18.8 million in the prior year period.
- Beyond revenue, we are also reaffirming our full-year adjusted EBITDA loss guidance of $35 million to $39 million.
- Adjusted operating loss was 10.8 million compared to 14.1 million for the first quarter of 2024, representing an improvement of 23% year over year.
Read full transcript analysis ›